JP2012524091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524091A5 JP2012524091A5 JP2012506099A JP2012506099A JP2012524091A5 JP 2012524091 A5 JP2012524091 A5 JP 2012524091A5 JP 2012506099 A JP2012506099 A JP 2012506099A JP 2012506099 A JP2012506099 A JP 2012506099A JP 2012524091 A5 JP2012524091 A5 JP 2012524091A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- ethyl
- vida
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 29
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims 22
- 201000010099 disease Diseases 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- MYBBQDZJFMXJAO-UHFFFAOYSA-N C1CC11C(CCCC1O)O Chemical compound C1CC11C(CCCC1O)O MYBBQDZJFMXJAO-UHFFFAOYSA-N 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 7
- -1 3-hydroxy-3-methylbutyl Chemical group 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 4
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 4
- 208000007536 Thrombosis Diseases 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 230000008694 endothelial dysfunction Effects 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 201000001474 proteinuria Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000013038 Hypocalcemia Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 201000009623 Myopathy Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000005750 disease progression Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 230000000705 hypocalcaemia Effects 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000012672 seasonal affective disease Diseases 0.000 claims 2
- 208000031019 skin pigmentation disease Diseases 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 229910052717 sulfur Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 102000009310 vitamin D receptors Human genes 0.000 claims 2
- 108050000156 vitamin D receptors Proteins 0.000 claims 2
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 5
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 2
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- BUBJBZBBZMZYHZ-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)C[Si](C)(Cl)C(C)(C)C Chemical compound CC(C)(C)[Si](C)(C)C[Si](C)(Cl)C(C)(C)C BUBJBZBBZMZYHZ-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17016009P | 2009-04-17 | 2009-04-17 | |
| US61/170,160 | 2009-04-17 | ||
| PCT/US2010/030777 WO2010120698A1 (en) | 2009-04-17 | 2010-04-12 | Vitamin d receptor agonists and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012524091A JP2012524091A (ja) | 2012-10-11 |
| JP2012524091A5 true JP2012524091A5 (cg-RX-API-DMAC7.html) | 2013-05-16 |
| JP5665848B2 JP5665848B2 (ja) | 2015-02-04 |
Family
ID=42710758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506099A Active JP5665848B2 (ja) | 2009-04-17 | 2010-04-12 | ビタミンd受容体アゴニストとその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20120115824A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2419403B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5665848B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102482210B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010236642B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2758698C (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ595727A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010120698A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8993547B2 (en) * | 2011-06-14 | 2015-03-31 | Wisconsin Alumni Research Foundation | 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses |
| CN105456278A (zh) * | 2014-09-03 | 2016-04-06 | 欣凯医药科技(上海)有限公司 | 一种抑制食欲的活性维生素d类似物 |
| CN105384765A (zh) * | 2014-09-04 | 2016-03-09 | 欣凯医药科技(上海)有限公司 | 奎宁酸内酯衍生物的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1559708A (en) * | 1924-04-11 | 1925-11-03 | Kelsey Walter Harrison | Mattress and method of making the same |
| JP3759639B2 (ja) * | 1994-04-11 | 2006-03-29 | 中外製薬株式会社 | 22−チアビタミン▲d3▼誘導体 |
| JPH10182597A (ja) * | 1996-10-29 | 1998-07-07 | Sumitomo Pharmaceut Co Ltd | 異性化ビタミンd誘導体 |
| US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| WO1998052574A1 (en) * | 1997-05-22 | 1998-11-26 | Cephalon, Inc. | Vitamin d analogues and their neuronal effects |
| GB9819764D0 (en) * | 1998-09-10 | 1998-11-04 | Oxagen Limited | Method |
| IT1311921B1 (it) * | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
| US6673782B2 (en) * | 1999-04-29 | 2004-01-06 | Wisconsin Alumni Research Foundation | Treatment of systemic lupus erythematosis |
| US20030195175A1 (en) * | 2002-03-25 | 2003-10-16 | Deluca Hector F. | Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone |
| EP1559708A4 (en) * | 2002-10-10 | 2006-07-19 | Wisconsin Alumni Res Found | 2,2-DISUBSTITUTED 1A, 25-DIHYDROXY-19-NORVITAMINE D DERIVATIVE |
| WO2004067504A1 (ja) * | 2003-01-31 | 2004-08-12 | Chugai Seiyaku Kabushiki Kaisha | 2位置換ビタミンd誘導体 |
| US6894037B2 (en) * | 2003-07-03 | 2005-05-17 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses |
| US20050209203A1 (en) * | 2003-07-30 | 2005-09-22 | Jin Tian | Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease |
| US8377913B2 (en) * | 2007-11-20 | 2013-02-19 | Abbvie Inc. | Vitamin D receptor activators and methods of making |
-
2010
- 2010-04-12 EP EP10714143.4A patent/EP2419403B1/en active Active
- 2010-04-12 JP JP2012506099A patent/JP5665848B2/ja active Active
- 2010-04-12 NZ NZ595727A patent/NZ595727A/xx unknown
- 2010-04-12 AU AU2010236642A patent/AU2010236642B2/en active Active
- 2010-04-12 WO PCT/US2010/030777 patent/WO2010120698A1/en not_active Ceased
- 2010-04-12 CA CA2758698A patent/CA2758698C/en active Active
- 2010-04-12 US US13/264,280 patent/US20120115824A1/en not_active Abandoned
- 2010-04-12 CN CN201080027380.8A patent/CN102482210B/zh active Active
-
2018
- 2018-04-09 US US15/948,359 patent/US20180327354A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2769327C2 (ru) | Модуляторы интегрированного сигнального пути стресса | |
| JP7802770B2 (ja) | Jak阻害剤を調製するための方法及び中間体 | |
| AU5162690A (en) | Novel benzimidazole derivatives | |
| JP2007197460A (ja) | 高コレステロール血症治療用の医薬組成物 | |
| JP2011506588A5 (cg-RX-API-DMAC7.html) | ||
| CA2852615A1 (en) | Novel substituted imidazopyrimidines as gpbar1 receptor modulators | |
| JPWO2010107115A1 (ja) | グリシントランスポーター阻害物質 | |
| JPH10182583A (ja) | 新規ヒドロキサム酸誘導体 | |
| JP2018535260A (ja) | キナーゼ阻害剤およびその中間体の調製方法 | |
| JP7200005B2 (ja) | 飽和環縮合ジヒドロピリミジノン又はジヒドロトリアジノン化合物及びその医薬用途 | |
| CN1455766A (zh) | 治疗免疫疾病的新的1,2-二苯基乙烯衍生物 | |
| JP2013536798A5 (cg-RX-API-DMAC7.html) | ||
| WO2019131582A1 (ja) | 含窒素6員環化合物 | |
| JP2011516523A (ja) | 新規エストロゲン受容体リガンド | |
| JPH11193273A (ja) | 神経伝達物質放出増強薬としての新規な非環式アミド類 | |
| CN102448932B (zh) | 氮杂环丁酮类化合物及医药应用 | |
| CN1317265C (zh) | 氰基丙烯酸酯衍生物及制备方法和生物活性 | |
| KR20100087931A (ko) | 로슈바스타틴의 전구체 및 그의 제조 방법 | |
| JP2022501386A (ja) | ピラゾール化合物を製造する方法 | |
| CN109134432B (zh) | 氘代抗抑郁药物 | |
| JP7381136B2 (ja) | 高血圧症及び/又は線維症を処置するための組成物 | |
| JP6216385B2 (ja) | 3,4−二置換オキサゾリジノン誘導体及びカルシウム活性化カリウムチャネルの阻害薬としてのそれらの使用 | |
| JPH02229168A (ja) | ピラゾロン誘導体 | |
| JP2010529052A (ja) | ジ(ヘテロ)アリールシクロヘキサン誘導体、それらの製造、それらの使用及びそれらを含む薬剤組成物 | |
| EA017306B1 (ru) | Селективный агонист tr-бета 1 |